6-fluoro-3-methylquinoline-2,4-diol | 345913-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-fluoro-3-methylquinoline-2,4-diol
• 英文别名: 6-Fluoro-2-hydroxy-3-methyl-1,4-dihydroquinolin-4-one；6-fluoro-4-hydroxy-3-methyl-1H-quinolin-2-one
• CAS: 345913-71-5
• 化学式: C₁₀H₈FNO₂
• 分子量: 193.177
• InChiKey: WVJLSQVDFHEJNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.3±42.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-fluoro-3-methylquinoline-2,4-diol 在 thioxanthenone 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.0h， 生成 9-fluoro-3a,4a-dimethyl-3,3a,4,4a-tetrahydro-2H-furo[2',3':2,3]cyclobuta[1,2-c]quinolin-5(6H)-one
  参考文献：
  名称：

  3-烷基喹诺酮与4-O-链状烯烃和丙二烯的可见光介导的对映选择性光反应。

  摘要：

  当在手性敏化剂的存在下用可见光照射时，标题化合物会发生分子内[2 + 2]光环加成反应。在低至0.5 mol％的催化剂负载量下，可在一个步骤中最多形成四个定义的立体异构中心（14个实例为链状烯烃，6个实例为烯丙基，产率为72-99％，ee为81-99％）。3-位烷基对于反应成功至关重要，因为它会导致三重态能量显着降低。

  DOI：

  10.1021/acs.orglett.0c01065
• 作为产物：
  描述：

  4-氟苯胺 、 甲基丙二酸二乙酯 以 二苯醚 为溶剂， 以71%的产率得到6-fluoro-3-methylquinoline-2,4-diol
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r

文献信息

• Quinolone compounds for use in treating viral infections
  申请人：——

  公开号：US20030069271A1

  公开（公告）日：2003-04-10

  The present invention relates to quinolone compounds and their use in the treatment of viral infections.

  本发明涉及喹诺酮化合物及其在治疗病毒感染中的应用。
• Synthesis of Azocane- and Oxocane-Annulated Furans by a [2+2] Photocycloaddition–Ring-Opening Cascade
  作者：Thorsten Bach、Xinyao Li、Christian Jandl

  DOI：10.1055/s-0040-1705957

  日期：2021.2

  coumarin derivatives by a cascade reaction (12 examples, 90–98% yield). The cascade comprised a [2+2] photocycloaddition which occurred upon sensitized irradiation at λ = 420 nm (or direct UV irradiation at λ = 366 nm) and a subsequent acid-catalyzed ring-opening reaction. A variety of substituents are compatible with the conditions and a 3-alkyl group in the coumarin (or quinolone) is crucial to achieve

  通过级联反应，由容易获得的喹诺酮和香豆素衍生物合成标题化合物（12个实例，收率90-98％）。级联包含[2 + 2]光环加成，该加成发生在λ= 420 nm的敏化辐射（或λ= 366 nm的直接紫外线辐射）和随后的酸催化开环反应中。多种取代基与条件相容，香豆素（或喹诺酮）中的3-烷基对于实现高化学选择性至关重要。开环成功的关键是形成一个4,5,5a-三氢环丁2 H-呋喃，它含有一个应变的桥头双键，该双键源于拴在起始材料4位上的烯基。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Cushing Timothy D.

  公开号：US20100331293A1

  公开（公告）日：2010-12-30

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、干燥综合征和自身免疫性溶血性贫血，包括各种过敏症状，本发明还提供了治疗与p110δ活性有关的、依赖于或与之相关的癌症的方法，包括但不限于白血病，如急性髓系白血病（AML）、髓增生异常综合征（MDS）、髓增生性疾病（MPD）、慢性髓性白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1244629A2

  公开（公告）日：2002-10-02
• 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS
  申请人：Amgen, Inc

  公开号：EP2445886B1

  公开（公告）日：2016-03-30